Cantor Fitzgerald reiterates Overweight rating on Trulieve Cannabis, $15 price target

Cantor Fitzgerald maintained an Overweight rating on Trulieve Cannabis with a $15 price target, suggesting a 37.4% upside from the Oct 22 close. The firm cited Trulieve's strong operational infrastructure, market leadership, and growth potential, including regulatory catalysts.

Original reporting
Published Oct 23, 2026, 10:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cantor Fitzgerald reiterates Overweight rating on Trulieve Cannabis, $15 price target — source image
Decision brief

The 30-second read

Med
01

Why it matters

The analyst's reiteration of Overweight and a $15 target may attract new buying, but investors should monitor regulatory developments in Texas.

02

Market read

A fresh analyst upgrade with a higher price target provides a short‑term catalyst for TRUV and may influence peer sentiment in the cannabis sector.

03

What to watch

Execution risk of expanding into adult‑use markets and the capital intensity of cultivation facilities.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Trulieve Cannabis (TRUV) operates 162 dispensaries in Florida and is a leading medical‑cannabis provider.

Market effects

May lift sentiment across the U.S. cannabis sector as analysts show confidence in medical‑cannabis operators.

Potentially benefits Florida‑focused cannabis stocks given Trulieve's strong presence in the state.

Limited to U.S. cannabis equities; no broader macro impact.

Counterpoint

The rating could be premature if regulatory approvals in Texas stall, leaving the target overly optimistic.

Key entities

  • Cantor Fitzgerald

    Equity research firm issuing the rating.

  • Trulieve Cannabis

    U.S. medical cannabis operator.

Related articles

$TRLVHigh

Trulieve (TRLV) Q3 2026 Earnings Call Transcript

Trulieve (TRLV) reported Q3 2026 earnings exceeding guidance, with $230M revenue (4% YoY growth), 64% gross margin, and $89M adjusted EBITDA. The company benefited from federal rescheduling of medical marijuana to Schedule III, enabling DEA registration, tax relief, and NYSE listing. Trulieve also repaid $65M in debt, improving cash flow. The company is expanding in Georgia and Texas, with strategic initiatives focused on access, growth, and product portfolio.

$TRLVHigh

Trulieve Reports Third Quarter 2026 Results

Trulieve Cannabis Corp. (TRLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Trulieve Reports Third Quarter 2026 Results • Third quarter revenue of $230 million, with 64% gross margin • Cash flow from operations of $183 million and free cash flow of $120 million* in first nine months of 2026 • Received final DEA registrations pursuant to fina

High

Federal drug officials register Trulieve's medical marijuana dispensaries

Trulieve Cannabis Corp. reported Q3 2026 revenue of $230 million, with a 64% gross margin. The company received final DEA registrations for its medical marijuana dispensaries following the rescheduling of cannabis to Schedule III. Trulieve also repaid $65 million in mortgage notes and operates 208 retail dispensaries. CEO Kim Rivers highlighted milestones unlocked by the rescheduling, including tax benefits and NYSE listing.